-
Product Insights
Neuromuscular Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuromuscular Disorders - Drugs In Development, 2023’, provides an overview of the Neuromuscular Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromuscular Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Myasthenia Gravis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myasthenia Gravis - Drugs In Development, 2023’, provides an overview of the Myasthenia Gravis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
Myasthenia Gravis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery. The Myasthenia Gravis - Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and...
-
Company Insights
Disruptor Profile: TravelPerk S.L.
The report provides information and insights into TravelPerk S.L.'s, including - - Overview of the company and its product offering - Detailed insight into its business model, company type and headquarter - Information on fundings - Biography of top management